Deep 6 AI vs Triomics (2026)
Breadth against depth in trial matching. Deep 6 covers the whole trial lifecycle across therapeutic areas, reading unstructured notes, pathology, genomics and laboratory data to match patients and sites, and it quantifies how much decisive eligibility information lives in the unstructured half of the record. Triomics is oncology only and better evidenced for it, with peer reviewed validation in a recognised journal, every match traced back to the pathology and biomarker behind it, and the deepest workflow integration in this category. For a cancer centre where oncology trials are the programme, Triomics is doing the harder version of the job and can show its working. For a health system running trials across several specialties, buying an oncology tuned platform leaves the rest uncovered. Neither publishes how often an eligible patient never surfaces.
- It reads the whole chart with an oncology tuned platform and traces every match back to the pathology and biomarker that produced it, so a coordinator can check the reasoning rather than trust a score.
- Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in this category.
- The output lands where the oncology team already works rather than in a separate screening tool, which is the deepest integration position here.
- Coverage is not confined to oncology, so a health system running trials across several therapeutic areas gets one platform rather than a cancer specific one.
- It quantifies how much decisive eligibility information sits in unstructured data, which is the argument for reading notes rather than filtering codes.
- Functional breadth spans feasibility and cohort building as well as matching, so sponsors and sites use the same system.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Deep 6 AI and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Deep 6 AI | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2016 | 2021 |
| Headquarters | Pasadena, California, United States | San Francisco, California |
| Website | deep6.ai | triomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Deep 6 AI its top capability grade on AI Centrality. Set against Triomics, Deep 6 AI does not grade higher on any scored axis, though the two are level on AI Centrality, Security Certifications and Trust Center and Commercial Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Triomics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Deep 6 AI, Triomics grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Deep 6 AI or Triomics?
The AI Health Index grades Triomics higher than Deep 6 AI on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Deep 6 AI does not grade higher on any scored axis.
Where do Deep 6 AI and Triomics differ most?
The widest separation the AI Health Index records between Deep 6 AI and Triomics is on Model and Technology Transparency, where Deep 6 AI grades C and Triomics grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Deep 6 AI and Triomics grade the same?
The AI Health Index grades Deep 6 AI and Triomics the same on AI Centrality, Security Certifications and Trust Center and Commercial Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Deep 6 AI and Triomics not disclosed?
At the last review, at least one of Deep 6 AI and Triomics published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both should be asked for the false negative rate on eligibility screening, which neither publishes and which is the only measure of whether a matching system works: a patient who was eligible and never appeared costs a trial an enrolment and costs the patient an option, invisibly. Triomics publishes no security attestation or trust centre. Deep 6 publishes no attestation scoped to the platform, no business associate terms and no governance framework. Trial matching also inherits documentation bias, so patients with sparse or fragmented records are systematically less likely to be found regardless of their eligibility.